The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Target Advancement Program, 2016LRRK2 Mutations and the Development of Therapeutic LRRK2 Inhibitors
Study Rationale:
Mutations in the leucine-rich repeat kinase 2 (LRRK2) protein can cause an inherited form of Parkinson's disease (PD). Understanding how these mutations cause PD is complicated, as... -
Research Grant, 2016Evaluation of LRRK2 Kinase Activity in Blood Cells
Promising Outcomes of Original Grant:
Since LRRK2 is a major genetic risk factor for Parkinson's disease (PD), much work has been devoted to LRRK2 function in neurons. However, LRRK2 is abundantly... -
Research Grant, 2016MJFF Recruitment Centers of Excellence
Study Rationale:
Clinical trials and studies in Parkinson's disease (PD) are often limited by low enrollment of participants , increasing the time it takes to bring new therapies to the market. The... -
Research Grant, 2017Development of a Clinical Flow Cytometry Assay for Accurate and Selective Measurement of GBA1 Activity in Peripheral Blood Mononuclear Cells
Study Rationale:
A protein in the brain known as glucocerebrosidase may not work properly in those with Parkinson's disease (PD). Methods currently used to monitor the activity of this protein within... -
Research Grant, 2016Inhibition of Striatal-enriched Phosphate (STEP) to Improve Parkinson-related Cognitive Dysfunction
Promising Outcomes of Original Grant:
Our original funded project was designed to examine absorption and distribution of the STEP (Striatal-Enriched Phosphatase), a protein associated with several... -
LRRK2 Therapeutic and Safety Initiative, 2017The Effects of a LRRK2 Inhibitor on Alpha-synuclein-induced Dopamine Deficits in a Pre-clinical Model of Parkinson's Disease
Study Rationale:
In a previous study, we demonstrated that PFE360, an LRRK2 inhibitor, has neuroprotective benefits. However, several questions remain unanswered as follows: (1) Did the vehicle...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.